The US President, Donald Trump, announced reciprocal tariffs on over 180 countries, including India, on April 2, 2025. Trump imposed 26% reciprocal tariffs, half the rate India charges on US imports. Donald Trump has exempted pharmaceutical imports from the reciprocal tariff. As a result, the Nifty Pharma Index rose 4.31% to 21,854.90 at 09:40 AM. All 20 stocks on the Nifty Pharma index were in green, where Gland Pharma, Lupin, Aurobindo Pharmaceuticals, Sun Pharma and Natco Pharma were the top gainers
| Company Name | US Revenue (%) in FY24 |
| Gland Pharma | 54 |
| Aurobindo Pharma | 48 |
| Lupin | 37 |
| Dr Reddy’s Laboratories | 48 |
| Zydus Lifesciences | 46 |
On April 3, 2025, Gland pharma share price rose ~9%, reaching a day high of 1,767.70. Other pharma stocks, such as Aurobindo Pharma, Lupin, Dr Reddy’s, and Zydus Lifesciences, rose over 5% at 09:45 AM.
As of November 2024, the Indian pharmaceutical industry ranked the 3rd largest in the world by production volume. Over the years, it has developed into a robust sector, growing at a compound annual growth rate (CAGR) of 9.43% over the past 9 years. India meets over 50% of the global demand for vaccines, 40% of the USA’s demand for generics, and 25% of the UK’s total medicine needs. The domestic industry consists of around 3,000 drug companies and approximately 10,500 manufacturing facilities, cementing India’s significant role in the global pharmaceuticals market.
The pharmaceutical sector is one of the top ten most attractive industries for foreign investment in India. Indian pharmaceutical exports reach over 200 countries worldwide, including highly regulated markets such as the USA, Western Europe, Japan, and Australia. India also supplied approximately 45 tonnes and 400 million tablets of hydroxychloroquine to around 114 countries globally.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Apr 3, 2025, 9:52 AM IST
Sachin Gupta
Sachin Gupta is a Content Writer with 6+ years of experience in the stock market, including global markets like the US, Canada, and Australia. At Angel One, Sachin specialises in creating financial content that simplifies complex market trends. Sachin holds a Master's in Commerce, specialising in Economics.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
